Form 4: IO Biotech Director Kathleen Glaub Granted 35,144 Stock Options

IO Biotech, Inc. Director Kathleen Sereda Glaub has been granted 35,144 stock options with an exercise price of $1.50, which are set to vest on June 5, 2026.

Summary

• Kathleen Sereda Glaub, a Director of IO Biotech, Inc. (IOBT), acquired 35,144 stock options on June 5, 2025.
• The stock options have an exercise price of $1.50 per share.
• These options are scheduled to vest on June 5, 2026, contingent upon Ms. Glaub's continued service to the company.
• The options have an expiration date of June 5, 2035.
• A significant clause allows for 100% acceleration of vesting upon a change of control of IO Biotech, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard equity grant to a director, aligning their interests with shareholders. It is a routine filing and does not indicate any immediate operational or financial changes, but rather a continuation of compensation practices.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term performance.
• The acceleration clause upon a change of control provides an additional incentive for the director in potential M&A scenarios.

Negatives

• No explicit negative information is contained within this Form 4 filing, as it primarily reports an equity grant.

Risks

• The vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before the vesting date.
• The value of the options is dependent on the future market price of IO Biotech's common stock exceeding the $1.50 exercise price; if the stock price remains below this, the options may hold no intrinsic value.

Future Outlook

The grant of these stock options, with a vesting period extending to June 2026, indicates an expectation of continued service from Director Kathleen Sereda Glaub and aligns her future compensation with the company's long-term performance.

Management Comments

• The filing indicates a standard equity grant to a director, reflecting the company's compensation strategy to incentivize long-term commitment and performance.

Industry Context

Equity grants, particularly stock options, are a common form of compensation for directors and executives in the biotechnology industry. This practice aims to align the interests of leadership with those of shareholders, encouraging growth and value creation in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in corporate governance and executive compensation across various industries, including biotechnology.
• The vesting schedule and change of control acceleration clauses are typical features designed to retain talent and provide incentives for value creation, comparable to compensation structures observed in companies like Moderna, BioNTech, or other clinical-stage biotech firms, though specific grant sizes and exercise prices vary based on company stage, market capitalization, and individual roles.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Kathleen Sereda Glaub, a Director of IO Biotech, Inc., constitutes a related party transaction as it involves an equity grant from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder value, potentially leading to better long-term performance.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The stock options are scheduled to vest on June 5, 2026, subject to continued service.

Key Dates

Keywords

IO Biotech, IOBT, Kathleen Sereda Glaub, Stock Options, Form 4, Insider Transaction, Equity Grant, Director Compensation, Vesting, Change of Control